Home/Filings/4/0001209191-24-000807
4//SEC Filing

Nolan Sean P. 4

Accession 0001209191-24-000807

CIK 0001806310other

Filed

Jan 3, 7:00 PM ET

Accepted

Jan 4, 4:41 PM ET

Size

8.6 KB

Accession

0001209191-24-000807

Insider Transaction Report

Form 4
Period: 2024-01-02
Nolan Sean P.
DirectorChief Executive Officer
Transactions
  • Award

    Employee Stock Option (right to buy)

    2024-01-02+1,184,6881,184,688 total
    Exercise: $1.71Exp: 2034-01-02Common Stock (1,184,688 underlying)
  • Award

    Common Stock

    2024-01-02+1,184,6881,185,858 total
Holdings
  • Common Stock

    (indirect: See Footnote)
    1,535,545
Footnotes (3)
  • [F1]Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 2, 2025, subject to the Reporting Person's continuous service through each applicable vesting date.
  • [F2]The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of the LLC and has shared voting and investment power with respect to the shares held by the LLC.
  • [F3]25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2025 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

Issuer

Taysha Gene Therapies, Inc.

CIK 0001806310

Entity typeother

Related Parties

1
  • filerCIK 0001569926

Filing Metadata

Form type
4
Filed
Jan 3, 7:00 PM ET
Accepted
Jan 4, 4:41 PM ET
Size
8.6 KB